Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Other Events
Item 8.01 Other Events
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Files An 8-K Other Events
On August 27, 2019, Pacific Western Bank (“Pacific Western”) delivered to Cidara Therapeutics, Inc. (the “Company”) a letter relating to the Loan and Security Agreement between the Company and Pacific Western, dated as of October 3, 2016, as amended on June 13, 2018 and July 27, 2018 (the “Loan Agreement”). The letter extends to October 15, 2019 the deadline for the Company and Pacific Western to execute an amendment to Section 6.7(b) of the Loan Agreement that memorializes a new financial covenant and/or milestone for the 2019 fiscal year and all subsequent fiscal years.
About Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.
